Site Editor

Gregory J. Riely, MD, PhD


Aaron Lisberg, MD, on TROPION-Lung01 Trial and Antibody-Drug Conjugates

Posted: Thursday, February 1, 2024

Aaron Lisberg, MD, of the University of California, Los Angeles, discusses the findings of the TROPION-Lung01 trial and comparing the antibody-drug conjugate datopotamab deruxtecan with standard therapies for advanced or metastatic NSCLC.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.